Abstract:ObjectivesThe proarrhythmic risk of QT prolonging drugs varies significantly. However, the mechanisms responsible for the high or low risk of drug-induced arrhythmias remain unknown. In this study, we tested our hypothesis that a proarrhythmic window exists for drugs that block multiple ion channels, which may be a cause of drugs with a high or low risk of proarrhythmia. Based on date from single cell research, tolterodine (a bladder inotropic drug), amiodarone and ranolazine are used as multiple channel inhibitors.MethodsHearts from New Zealand White female rabbits weighing 2.5-3.5 kg were isolated, perfused in a Langendorff mode with modified Krebs-Hensileit solution. The atrioventricular nodal area was thermally ablated to produce complete atrioventricular block, and then heart was paced at a frequency of 1 Hz. Multiple channel monophasic action potentials (MAP) and pseudo 12-lead electrocardiograms (ECGs) were recorded. MAPD90 and transmural dispersion of repolarization (TDR) were measured.ResultsIn the absence of a drug (control), MAPD90s recorded from epicardium and endocardium of left ventricule were 186.5 ± 5.5 and 206.5 ± 5.1 ms (n = 8), respectively. Administration of tolterodine from 10 nM to 600 nM, MAPD90 was increased, in concentration dependent manners, from 196.7.0 ± 4.9 to 281.7 ± 26.8 ms, and 220.0 ± 4.6 ms to 350.6 ± 18.7 ms (n = 8, p < 0.001 vs control), respectively. However, when the concentration of tolterodine increased to 10 µM from 600 nM, MAPD90 was decreased to 224.2 ± 5.9 and 252.5 ± 5.9 ms (n = 8), respectively. In addition, the incidence of TdP was correlated with the biphasic changes of MAPD90. Polymorphic ventricular tachycardias (PVT) were recorded at concentrations of 0.1-1 µM. There was no arrhythmia in the presence of 100-600 nM and 3-10 µM tolterodine. In contrast, amiodarone caused PVT only at 0.03-0.3 µM in the presence of late INa enhancer ATX-II. Ranolazine prolonged MAPD90 in absence, but not in the presence of ATX-II and caused no PVT.ConclusionsThe biphasic pattern of MAPD induced by tolterodine, as well as by amiodarone and ranolazine, suggests that a proarrythmic window exists in multiple ion channel blockers, which may be a determinator of the risk of drug-induced proarrhythmias. The mechanism of the biphasic change may be attributed to the relative selectivity of drug on IK and late INa.

How to Determine Cardiac Ion Channels Targeted by Drugs Using the Isolated Rabbit Ventricular Wedge Model

Assessment of Drug-Induced Proarrhythmia: the Importance of Study Design in the Rabbit Left Ventricular Wedge Model.

Differentiating electrophysiological effects and cardiac safety of drugs based on in vitro electrocardiogram: A blinded validation

Automated Tight Seal Electrophysiology for Assessing the Potential Herg Liability of Pharmaceutical Compounds

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Preclinical Assessment of Drug-Induced Proarrhythmias: Role of the Arterially Perfused Rabbit Left Ventricular Wedge Preparation

Application of an in Vitro Model for Early Detection of Cardiac Sodium Channel Blocking Liabilities

Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias.

Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models.

A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).

High-Throughput Drug Screening System Based on Human Induced Pluripotent Stem Cell-Derived Atrial Myocytes ∼ A Novel Platform to Detect Cardiac Toxicity for Atrial Arrhythmias

GW24-e2999 Proarrhythmic window of a drug determines the risk of multiple ion channel inhibitors

Modulating the voltage sensor of a cardiac potassium channel shows antiarrhythmic effects

Electrophysiological Changes in the Rabbit Ventricular Wedge and Human-Induced Pluripotent Stem-Cell Derived (IPSC) Cardiomyocytes Translate to Severe Arrhythmia Observed in a Canine Toxicology Study, Not Predicted by Standard In Vitro Ion Channel Assays

Role of arterially perfused rabbit left ventricular wedge preparation in assessment of drug-induced proarrhythmic liability

Phenomenological analysis of simple ion channel block in large populations of uncoupled cardiomyocytes

Ventricular voltage-gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation

Cross clinical-experimental-computational qualification of in silico drug trials on human cardiac purkinje cells for proarrhythmia risk prediction

Antiarrhythmic Peptide AAP 10 Prevents Ventricular Arrhythmia in Rabbit LQT 2 Model